$1,318.00
This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals, a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, licensing and asset acquisition deals, a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
8 TREATMENT
8 Non-pharmacological therapy
8 Pharmacological therapy
10 EPIDEMIOLOGY
14 MARKETED DRUGS
20 PIPELINE DRUGS
25 KEY UPCOMING EVENTS
26 KEY REGULATORY EVENTS
26 Keeping Track: Supernus Requests Adult Indication For ADHD Drug Qelbree
27 PROBABILITY OF SUCCESS
28 LICENSING AND ASSET ACQUISITION DEALS
28 Ignis Therapeutics Licenses NeuroSigma Monarch eTNS System for ADHD
28 With China CNS Plans, SK Biopharm Completes Strategy For Key Markets
29 REVENUE OPPORTUNITY
32 CLINICAL TRIAL LANDSCAPE
33 Sponsors by status
34 Sponsors by phase
36 BIBLIOGRAPHY
38 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of ADHD, 2021–30
20 Figure 2: Overview of pipeline drugs for ADHD in the US
20 Figure 3: Pipeline drugs for ADHD, by company
21 Figure 4: Pipeline drugs for ADHD, by drug type
21 Figure 5: Pipeline drugs for ADHD, by classification
25 Figure 6: Key upcoming events in ADHD
27 Figure 7: Probability of success in the ADHD pipeline
32 Figure 8: Clinical trials in ADHD
32 Figure 9: Top 10 drugs for clinical trials in ADHD
33 Figure 10: Top 10 companies for clinical trials in ADHD
33 Figure 11: Trial locations in ADHD
34 Figure 12: ADHD trials status
35 Figure 13: ADHD trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of ADHD, 2021–30
13 Table 2: Prevalent cases of persistent ADHD in adults, 2021–30
15 Table 3: Marketed drugs for ADHD
22 Table 4: Pipeline drugs for ADHD in the US
30 Table 5: Historical global sales, by drug ($m), 2017–21
31 Table 6: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!